Media Releases

Find out about our current activities

Click on the media releases below to find out more about our current activities.

13.07.2016 - Registration Open for New Frontiers in 3D Cell Culture-based Screening Technologies Conference

Registration Open for New Frontiers in 3D Cell Culture-based Screening Technologies Conference

Schlieren, Switzerland, July 13, 2016 – Inaugural meeting, organized by InSphero AG, NCATS, CAAT, and Promega Corp., to be held Thursday, October 13, 2016 in Baltimore, MD.  PDF file

Registration and abstract submission for the inaugural New Frontiers in 3D Cell Culture-based Screening Technologies: Towards greater physiological relevance conference open today via the conference website. Conceived and organized by InSphero AG, the National Center for Advancing Translational Sciences, part of the National Institutes of Health (NIH), the Centers for Alternatives to Animal Testing (CAAT), and Promega Corp., the conference will feature keynote presentations by Dr. Michael Gottesman of the NIH’s National Cancer Institute’s Center for Cancer Research, and Dr. Thomas Hartung of the Johns Hopkins Bloomberg School of Public Health and Director of CAAT.

The one-day symposium, to be held Thursday, October 13, 2016 at the Johns Hopkins University Charles Commons in Baltimore, Maryland, will feature sessions on drug discovery and toxicology, with invited presentations from Novartis, the Hubrecht Institute, Merck, and the NIH’s National Institute of Environmental Health Sciences (NIEHS). Additional speakers will be selected from attendee abstracts submitted for podium presentation, with abstracts for consideration due by August 1, 2016. Abstracts for poster presentations will be accepted until August 15, 2016.

Dr. Jens Kelm, Chief Scientific Officer of InSphero AG and member of the New Frontiers Scientific Advisory Board, says the conference fills what has been a clear gap in scientific forums by focusing on a global view of 3D cell culture technologies. “The goal of this new conference is to assemble an international forum of leaders in the field of 3D tissue models. We aim to offer a balanced perspective of state-of-the-art systems, their adoption and implementation in drug discovery and safety testing, and potential regulatory hurdles to consider as 3D models become standardized and more mainstream.” Kelm notes that the New Frontiers Conference plans to alternate between US and European host cities on an annual basis.

To register or receive more details about the conference, visit the New Frontiers in 3D Cell Culture-based Screening Technologies website.

For more information about InSphero, visit www.insphero.com.  

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jens M. Kelm
CSO and Co-founder, InSphero AG
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

 

11.07.2016 - InvitroCue Commences Pancreatic Toxicity Assay Development

Logo

InvitroCue Commences Pancreatic Toxicity Assay Development

11 July 2016 – InvitroCue (ASX:IVQ), a leader in advanced bio-analytics, has progressed its technology in modelling multi-organ toxicity by developing a novel assay to detect pancreatic toxicity. The assay is part of a strategic collaboration with InSphero AG (Switzerland), the world’s leading provider of assay-ready 3D microtissues for more predictive drug discovery and development. This builds on a previous MOU between InSphero and InvitroCue on the in vitro cell-based hepatotoxicity assay. PDF File

InvitroCue has a history of pioneering technology and establishing industry firsts for liver-related testing assays through its partnerships with leading pharmaceutical and biotech companies. As part of InvitroCue’s objective to cater for increasing demand for more innovative products and services it has also introduced disease-specific drug screening services related to non-alcoholic steatohepatitis, leishmaniasis, malaria and perfused human liver tissue. The strategic partnership with InSphero demonstrates the company’s ongoing commitment to deliver customer-centric innovation and best-in-class technological solutions.

“We aim to offer a convenient assay solution for our biopharmaceutical customers to accelerate preclinical anti-diabetic drug development and assessment of potential pancreatic toxicities associated with their metabolites,” commented Dr. Steven Fang, Executive Director of InvitroCue.

InSphero CEO and co-founder Dr. Jan Lichtenberg said, “The collaboration allows InvitroCue to leverage our next-generation 3D InSight™ Islet Microtissues as part of their toxicity testing services, and establishes important inroads as we continue to grow our business in the important Asia-Pacific Market.”

 

For more information, please contact:
Matthew Gregorowski, Citadel-MAGNUS
T: +61 2 8234 0100
This email address is being protected from spambots. You need JavaScript enabled to view it.


About InvitroCue

InvitroCue is an Australian-based biotechnology and life science services company. The Company focuses on the commercialisation of its analytics services using cell-based model and imaging based technology. Its cell-based services enable pharmaceutical and cosmetics companies to refine their drug, ingredient, compound or vaccine discovery efforts. Its digital pathology business offers solutions, including slide scanning and digitisation; image analytics of tissues and cell samples; pathology consultation with board certified pathologists, and telepathology via an online Web-based portal. It provides products and services in the field of in vitro drug metabolism and pharmacokinetic (DMPK), in vitro toxicology and digital pathology utilizing cell-based models and analytics. It offers image analytics services for liver disease applications. InvitroCue’s technology originated in Singapore’s Agency for Science, Technology and Research (A*STAR). InvitroCue has been developed and validated in collaborations with leading pharmaceutical companies and scientific collaborators. InvitroCue currently operates in Singapore and China and is listed on Australian Securities Exchange under the ticker IVQ. Website: www.invitrocue.com

16.06.2016 - Nature Scientific Reports Article Touts Versatility, Promise of 3D Human Liver Microtissues for Drug Development

Nature Scientific Reports Article Touts Versatility, Promise of 3D Human Liver Microtissues for Drug Development

Schlieren, Switzerland, June 16, 2016 – Liver spheroids display longer culture lifetime, liver-like functionality, and increased sensitivity for detection of hepatotoxic drugs.  PDF Version

Research published by the Karolinska Institute and collaborators as part of the European Community Innovative Medicine Initiative project (MIP-DILI) offers further, independent verification of the utility and promise of 3D liver microtissues for studying liver function, liver diseases and long-term drug-induced liver injury (DILI). The research was published last month in Nature Scientific Reports, an open-access journal.

The paper demonstrates the extended in vitro lifetime and organotypic characteristics of primary human hepatocytes (PHH) when cultured in a scaffold-free 3D configuration, displaying viability and liver-like functionality for up to five weeks in culture. Proteomic analysis revealed that inter-individual variability was retained between spheroids generated from different individual hepatocyte donors. The study also used the prolonged in vitro lifespan of 3D cultured hepatocytes to perform chronic exposure testing of known DILI-inducing drugs, and found they could predict toxicity at clinically-relevant doses. In addition, the spheroid model system proofed to be suitable for studying liver diseases such as cholestasis and steatosis.

Commenting on the publication, Dr. Jens M. Kelm, Chief Scientific Officer and co-founder of InSphero AG says the paper, “Reinforces to the scientific community the benefits of 3D liver microtissues for the purpose of safety assessment during drug development. 3D liver models show enhanced culture lifetime in comparison to standard 2D cultured hepatocytes. This allows for long-term, repeat dose exposure studies, and enhances the sensitivity and predictive power of the model.”

InSphero uses its patent-pending 3D Select™ Process to enable industrial-scale production of 3D liver microtissues for in vitro liver research and DILI testing conducted by the world’s largest pharmaceutical and chemical companies. Dr. Kelm notes that InSphero has performed similar proteomic and genomic characterization of its 3D InSight™ Human Liver Microtissues grown over 28 days in culture, results presented at the EuroTox Annual Meeting in 2015. InSphero’s 3D Select™ Process yields liver microtissues with consistent morphology and viability by ensuring only the healthiest cells incorporate into tissues, a critical difference from conventional methods. “Cryopreserved hepatocytes contain large numbers of necrotic and functionally compromised cells. This percentage varies greatly between donor lots and vendors, making it challenging to make uniform microtissues in the numbers needed for industrial-scale testing. Through our 3D Select™ Process, we remove these compromised cells prior to the aggregation step, making microtissue formation more reliable, while improving morphology and viability. This translates to a more robust, mechanistically accurate in vitro model that enables testing standardization across multiple sites, and across the industry as a whole.”

To find out more about 3D InSight™ Human Liver Microtissues, the 3D Select™ Process, or to learn more about InSphero visit www.insphero.com.

For more information about InSphero, visit www.insphero.com.  

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jens M. Kelm
CSO and Co-founder, InSphero AG
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

16.03.2016 - InSphero Launches Multi-donor Human Liver Microtissues for Prediction of Drug-induced Liver Injury

InSphero Launches Multi-donor Human Liver Microtissues for Prediction of Drug-induced Liver Injury

Schlieren, Switzerland, March 16, 2016 – 3D human liver microtissues comprised of pooled hepatocytes from multiple donors offers more genetically diverse model for DILI detection and prediction.  PDF Version

InSphero AG, the leading supplier of easy-to-use solutions for production, culture, and assessment of organotypic 3D cell culture models, today announced the launch of 3D InSight™ Multi-donor Human Liver Microtissues, further expanding the company’s catalog of organotypic 3D models produced using their patented hanging-drop production technology. The newest liver model is being introduced at the Society of Toxicology’s 55th Annual Meeting and ToxExpo being held this week in New Orleans, Louisiana. Failure of drugs during late phases of the drug discovery process costs the pharmaceutical industry billions of dollars each year, and drug-induced liver injury (DILI) is the primary reason for post-market drug withdrawal. InSphero 3D InSight™ Human Liver Microtissues provide a more sensitive preclinical in vitro model for DILI detection and prediction, with the specificity to accurately distinguish between known hepatotoxicants and structurally-related non-toxic analogs. The new multi-donor microtissues offer the same structural and functional robustness of single-donor microtissues, but provide a more diverse genetic background to help mitigate bias in models resulting from naturally occurring variations in drug-metabolizing Cytochrome P450 enzymes.

Dr. Jens Kelm, InSphero Chief Scientific Officer and co-founder says, “By pooling hepatocytes from 5 male and 5 female donors, multi-donor microtissues more closely approximate the average human response, and extend donor lot availability to ensure a long-term supply of cells for microtissue production. This makes them an ideal tool for in vitro DILI detection and prediction, compound toxicity screening, mechanistic toxicology, and DMPK studies.”

Multi-donor microtissues are available as hepatocyte-only monocultures, or as co-cultures with Kupffer cells, enabling detection of immune-mediated toxicity.

To find out more about 3D InSight™ Multi-donor Human Liver Microtissues, or to learn more about InSphero visit www.insphero.com.

For more information about InSphero, visit www.insphero.com.  

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jens M. Kelm
CSO and Co-founder, InSphero AG
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

Images

multi donor modified2 no backgroundmulti donor icon balanced5

10.02.2016 - InSphero Contributes 3D Microtissue-based Assay Chapter to NCATS/NIH Assay Guidance Manual

InSphero Contributes 3D Microtissue-based Assay Chapter to NCATS/NIH Assay Guidance Manual

Schlieren, Switzerland, February 10, 2016 – Latest update of industry manual for development of high-throughput screening calls on scientists from leading 3D cell culture provider for standardized viability, toxicity protocols.  PDF Version

InSphero AG, the leading supplier of easy-to-use solutions for production, culture, and assessment of organotypic 3D cell culture models, has contributed a chapter in the NIH National Center for Advancing Translational Sciences (NCATS) Assay Guidance Manual, which describes best practices for adapting and standardizing high-throughput assays for use with 3D microtissues. The chapter, “In vitro 3D Spheroids and Microtissues: ATP-based Cell Viability and Toxicity Assays,” was co-authored by Dr. Monika Kijanska and Dr. Jens M. Kelm of InSphero, and appears in a 2016 update to the eBook published last week.

Dr. Terry Riss, Global Strategic Marketing Manager, Cell Health at Promega Corporation, and a contributing editor for the Assay Guidance Manual states, “The new chapter by Drs. Kijanska and Kelm provides expert guidance for scientists moving into the realm of using more physiologically relevant 3D cell culture model systems, and fills a long overdue gap in the content of the Assay Guidance Manual.” Dr. Kelm, Chief Scientific Officer and co-founder of InSphero said, “It was an honor to lend our expertise to such a well-recognized and widely accepted reference guide for cell-based assay and screening communities. It’s a great example of open innovation.” The chapter addresses considerations for choosing an appropriate 3D model, provides guidance on selection of reagents and protocol adaptations proven to work in a 3D setting, and gives specific examples of cell viability and toxicity assay results obtained with InSphero 3D InSight™ Human Liver Microtissues and Tumor Microtissues.

Early iterations of the manual were created by staff researchers at Eli Lilly and Company, but content for the Assay Guidance Manual is currently edited by 19 researchers representing 11 institutions, including NCATS and Lilly. The manual provides guidelines for scientists in academic, non-profit, government and industrial research interested in developing assays useful in screening molecules that modulate biological targets, pathways, or cellular phenotypes. Such molecules may serve as candidates for development of novel drugs for diseases such as cancer, diabetes, neurodegenerative disease, and rare genetic disorders.

For more information about InSphero, visit www.insphero.com.  

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Dr. Jens M. Kelm
CSO and Co-founder, InSphero AG
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU-ToxRisk and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

 

01.02.2016 - InSphero Inc. Streamlines 3D Microtissue Business Operations in US

InSphero Inc. Streamlines 3D Microtissue Business Operations in US

Schlieren, Switzerland, February 01, 2016 – US subsidiary of Swiss-based InSphero AG initiates direct product shipments, progresses towards full-scale US bioproduction capabilities. PDF Version

InSphero AGthe leading supplier of easy-to-use solutions for production, culture, and assessment of organotypic 3D cell culture models, has begun accepting orders and processing all financial transactions with customers in North America through its US subsidiary InSphero Inc. The February 1 transition immediately streamlines access to InSphero products and services for US-based customers, and positions the company to initiate operations in its recently completed US bioproduction laboratory in Brunswick, Maine.

Stewart Hunt, General Manager of InSphero Inc., states the transition, “Will dramatically simplify order fulfillment for customers in our largest market by allowing them to order directly from a US source. This eliminates customs processing, additional handling fees, as well as potential delays encountered by those currently using shipment brokers to manage direct international purchases.

The transition accompanies another milestone for InSphero Inc., which has assembled an expert team of 11 US-based employees over the past year. Says Hunt, “We’ve moved quickly, adding key scientific staff to lead the laboratory build-out, technology transfer, and initiate product manufacturing in our state-of-the-art Brunswick facility. Concurrently we have established an experienced team of sales managers, field application scientists, marketing, and product management professionals to provide responsive education and support to our North American customers.”

For more information about InSphero, visit www.insphero.com.  

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it. 

 

Stewart Hunt
General Manager, InSphero Inc
Phone +1 800-779-7558 ext. 101
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

 

25.01.2016 - InSphero and NCATS to Present Collaborative 3D Cancer Screening Study at SLAS2016 Annual Meeting

InSphero and NCATS to Present Collaborative 3D Cancer Screening Study at SLAS2016 Annual Meeting

Schlieren, Switzerland, January 25, 2016 – Study describes high-throughput compatible screening assay using 3D tumor microtissue models to classify efficacy, toxicity, and mechanism of action for compounds in NIH Oncology Library. PDF Version

InSphero AGthe leading supplier of easy-to-use solutions for production, culture, and assessment of organotypic 3D cell culture models, will present preliminary findings from studies in collaboration with the NIH National Center for Advancing Translational Sciences (NCATS) and NMI Technologietransfer GmbH, at today’s annual meeting of the Society for Laboratory Automation and Screening (SLAS) in San Diego, California. Data summarizing screens of 40 compounds from the NCATS Oncology Library in 3D ovarian and pancreatic tumor microtissues will be presented by InSphero CSO and co-founder Dr. Jens M. Kelm during Monday afternoon’s Assay Development & Screening poster session.

InSphero and NCATS announced a collaboration in 2014 to develop improved phenotypic high-throughput screening (HTS) methodologies incorporating highly biologically relevant 3D tumor microtissue models that more closely mimic the in vivo tumor microenvironment than traditional 2-dimensional monolayer cell culture. 3D tumor microtissue co-cultures from ovarian or pancreatic tumor cell lines with stromal fibroblasts were generated using InSphero’s patented hanging drop technology. Stromal fibroblasts were engineered to express a secreted reporter to simultaneously assess both anti-tumor efficacy and non-specific cytotoxicity. Initial findings from the collaboration confirmed more than 50% of the 40 compounds tested displayed greater potency against ovarian and pancreatic tumor cells grown as 3D microtissues than to the same cells grown in monolayer. Furthermore, the screen identified three compounds that showed anti-tumor efficacy in ovarian tumor microtissues only in the tumor/fibroblast co-culture model, highlighting the potential importance of mimicking heterogeneous tumor microenvironments when conducting such high-throughput in vitro screens. Dr. Kelm notes that incorporating advanced multi-cell type 3D models derived from these and other types of cancer is critical to improving the translational value of in vitro screens.

“Here we’ve established a multi-parametric phenotypic screening method that not only factors in tumor size and cell viability, but also discriminates between anti-tumor and non-specific toxic effects of compounds. Using these results, we can determine a therapeutic index value by which compounds are ranked for their potential efficacy and specificity toward a particular cancer, using models that more accurately reflect in vivo tumor biology.” In addition to Dr. Kelm’s poster presentation, InSphero microtissues and high-throughput screening and imaging concepts will be featured during several events at SLAS2016, including two exhibitor tutorials and other collaborative posters.

For more information about NCATS, visit www.ncats.nih.gov.

For more information about InSphero, visit www.insphero.com.  

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it. 

 

Dr. Jens M. Kelm
Chief Scientific Officer and Co-founder
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

 

23.10.2015 - InSphero’s CEO Jan Lichtenberg wins Entrepreneur Of The Year™ 2015

InSphero's CEO Jan Lichtenberg wins Entrepreneur of the YearTM 2015

Schlieren, Switzerland, Oct 23, 2015 – Dr. Jan Lichtenberg, CEO and co-founder of InSphero AG received the Ernst & Young Entrepreneur of the YearTM 2015 award in the category "Emerging Entrepreneur". PDF Version

Dr. Jan Lichtenberg, CEO and co-founder of InSphero AG has been awarded the Swiss EY Entrepreneur of the YearTM 2015 award for his leadership in building the Schlieren-based 3D cell culture company into a world-leading technology provider that is helping to revolutionize drug development and chemical safety testing.

pic Jan for PR

Watch EY portrait video 

Winners in four categories: Service/Trade, Industry/High-Tech/Life Sciences, Emerging Entrepreneur and Family Business were selected from 15 finalists by an independent jury, and announced this past Saturday. The four winners stood apart for their company achievement, leadership strenght and convincing promotion of their company through professional and social engagement.

Since 1998 EY has tracked successful entrepreneurs in all sectors, branches, regions and markets within Switzerland. They're all courageous, innovative, willing to take risks, reliable, engaging and strong; they are the backbone of the Swiss national economy. EY Entrepreneur of the YearTM is the only entrepreneurial award program with a global dimension, with 60 participating countries around the world honoring entrepreneurial excellence.

A jury will elect the World Entrepreneur of the YearTM from the pool of national winners at the spring 2016 ceremony to be hosted in Monte Carlo.

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jens M. Kelm
CSO and co-founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

21.10.2015 - InSphero Receives € 750K Funding from EU-ToxRisk Consortium

InSphero Receives € 750K Funding from EU-ToxRisk Consortium

 

Schlieren, Switzerland, Oct 21, 2015 – In a large (€ 30 MM) H2020-supported collaborative project, leading 3D cell culture technology provider joins consortium to jointly foster more efficient, animal-free chemical safety assessment.  PDF Version

InSphero AG, the leading provider of easy-to-use solutions for production, culture, and assessment of organotypic 3D cell culture models, has been awarded € 750K in funding over six years as part of the € 30 MM EU-ToxRisk collaborative project funded by Horizon 2020.

An international consortium of 39 partner organisations will be funded by the European Commission to work on the integration of new concepts for regulatory chemical safety assessment. These new concepts involve cutting-edge human-relevant in vitro non-animal methods and in silico computational technologies to translate molecular mechanistic understanding of toxicity into safety testing strategies. The ultimate goal is to deliver reliable, animal-free hazard and risk assessment of chemicals

Coordinated by Bob van de Water, Professor of Toxicology at the University Leiden (The Netherlands), EU-ToxRisk has the ambition to become the flagship in Europe for animal-free chemical safety assessment. The project will integrate advancements in cell biology, omics technologies, systems biology and computational modelling to define the complex chains of events that link chemical exposure to toxic outcome. The consortium will provide proof of concept for a new mechanism-based chemical safety testing strategy with a focus on repeated-dose systemic toxicity as well as developmental and reproductive toxicity. Importantly, novel mechanism-based test methods will be integrated in fit-for-purpose testing batteries that are in line with the regulatory framework and will meet industrial implementation. EU-ToxRisk will develop new ab initio quantitative risk assessment approaches based on understanding of so-called “Adverse Outcome Pathways” incorporating all mechanistic toxicity data available in the public domain. It will also achieve a rapid improvement of so-called “read across” approaches as the most important data-gap filling and hence animal-saving alternative method at present. Thus, the project strives towards faster safety evaluation of the many chemicals used by industry and the society.

InSphero CSO and co-founder Dr. Jens Kelm says the award, “serves as a key indicator of the value being placed on advanced 3D models in the project, as they provide greater longevity to enable repeat-dose testing in vitro, and improved biological relevance and mechanistic accuracy relative to traditional 2D cell culture models.   Much of the in silico and predictive modelling algorithms are based upon large amounts of data accumulated using 2D models, so 3D microtissues stand to be a valuable resource in helping to update and refine that data to increase its predictive value.  We are excited to lend our expertise in developing and producing a diverse range of organotypic microtissues, implementing state-of-the-art 3D optimized assays, and integrating microtissues into Body-on-a-Chip systems to advance the aims of the consortium.” 

For more information about InSphero, visit www.insphero.com

 

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jens M. Kelm
CSO and co-founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

15.10.2015 - InSphero Adds Chief Financial Officer to Senior Management Team

InSphero Adds Chief Financial Officer to Senior Management Team

Schlieren, Switzerland, Oct 15, 2015 – Oliver Krähenbühl brings 25 years of finance experience in the technology industry, strengthens senior team at global leader in 3D cell culture. PDF Version

InSphero AG, the leading supplier of easy-to-use solutions for production, culture, and assessment of more organotypic 3D cell culture models, has appointed Oliver Krähenbühl to serve as Chief Financial Officer. Mr. Krähenbühl joins the InSphero senior management team having previously held CFO positions at HF Global Inc. New York, Canon, and JobCloud AG, the leading Swiss online professional recruiting company.

InSphero CEO and co-founder Dr. Jan Lichtenberg states the company “stands to benefit immediately from Oliver’s decades of experience, including 15 years at an executive management level and significant cross-Atlantic know-how. In Oliver we have gained a proven expert to guide us financially through our next phase of global trade and operational expansion, particularly following the recent securing of our Series C financing round. We are excited to have him as a member of our team.”

A native of Switzerland and a Swiss Certified Expert in International Accounting and Controlling, Mr. Krähenbühl earned his MBA at the University of Chicago - Booth School of Business. Prior to his previously held CFO positions, he served in various financial, systems integration and project management capacities at Hewlett Packard.

For more information about InSphero, visit www.insphero.com

 

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jan Lichtenberg
CEO and co-founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

13.10.2015 - InSphero Launches 14 Day Hepatotoxicity Testing Service

InSphero Launches 14 Day Hepatotoxicity Testing Service

Schlieren, Switzerland, Oct 13, 2015 – Monthly contract screening service simplifies long-term, repeat-dose testing of drugs in 3D human liver microtissues for global pharmaceutical market. PDF Version

InSphero AG, the leading supplier of easy-to-use solutions for production, culture, and assessment of organotypic 3D cell culture models, has launched a 14 Day Hepatotoxicity Testing Service designed to meet increased demand for contract screening in their patent-pending 3D InSight™ Human Liver Microtissues. The service streamlines toxicity testing of compounds in InSphero’s 3D liver microtissues by initiating regular screening runs on the first Tuesday of each month at a cost of $990 per compound.

The newest addition to the company’s growing portfolio of 3D InSight™ Services takes advantage of the more liver-like functionality and greater than 4 week in vitro lifespan of primary liver cells (hepatocytes and Kupffer cells) when co-cultured as 3D spheroids, allowing repeated dosing of compounds over the two week testing protocol. Such testing is unique to 3D cultures, as the same cells grown in 2D (monolayer) culture live only a matter of days, allowing only limited assessment of drug toxicities. The service quantifies total cellular adenosine triphosphate (ATP) as a measurement of cell viability, an assay routinely used to assess drug induced liver injury (DILI). Results for test compounds and defined control compounds are returned to the customer three weeks after initial dosing.

Since its commercial launch in 2010, InSphero has seen the rapid adoption of its 3D InSight™ Microtissues and Services by leading pharmaceutical, chemical and cosmetics companies. More recently, large pharma organizations have completed validation studies and begun converting from conventional assays to InSphero’s 3D microtissues.

Dr. Johannes Haugstetter, Director of Services for InSphero, says exposing cells to drugs over 14 days can reveal toxicity at lower doses than seen when only treated for a matter of hours or days, as in 2D hepatocyte assays. “Long-term exposure in 3D models more accurately predicts potential drug toxicity by mimicking native liver tissue and the repeated exposure to drugs that would be experienced by a patient repeatedly taking the drug. 14 Day Hepatotoxicity Testing provides more reliable evidence of a drug’s safety or potential toxicity, and does so at a fraction of the cost of animal models, which may not accurately reflect the response in humans. Growing acceptance of our liver microtissues as a more predictive and mechanistically relevant model necessitated the adoption of a convenient format for routine, long-term testing of compounds that emerge from primary screens.”

The 14 Day Hepatotoxicity Testing Service complements an array of InSphero standard and custom service offerings, including endpoints to determine functional and mechanistic drug toxicity in 3D microtissues derived from liver, pancreas, heart, brain and skin.

For more information about InSphero, visit www.insphero.com

 

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Johannes Haugstetter
Director of Services
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

29.09.2015 - InSphero Granted Hanging Drop Patent in United States

InSphero Granted Hanging Drop Patent in United States

Schlieren, Switzerland, September 29, 2015 – Patent establishes protection of InSphero GravityPLUSTM technology in all major global markets, key milestone for leading provider of 3D cell culture platforms, microtissues and services.  PDF Version

The United States Patent and Trademark Office (USPTO) officially granted InSphero AG full protection of its GravityPLUSTM hanging drop technology. InSphero, the world's leading developer of easy-to use solutions for organotypic 3D cell culture models and body-on-a-chip systems, now holds hanging drop patents in the world's major pharmaceutical and biotechnology markets, including the United States, Europe, China, Japan, and Singapore. The core patent WO2010031194 describes multi-well plates which allow the generation of hanging drops for 3D cel culture, using convenient top loading of the cell suspension.

InSphero commercialized the hanging drop technology as the GravityPLUS™ Hanging Drop System in 2010.  The system includes the GravityPLUS™ plate used for production of 3D spheroids in hanging drops, and also the companion GravityTRAP™ culture and assay plate, to which 3D microtissues are transferred for long-term culture and drug testing. 

Dr. Jan Lichtenberg, CEO and co-founder of InSphero, says that the favorable decision has been a long time coming for InSphero.  “We are excited the USPTO has recognized the originality of our design, and granted protection of the investment we have made into the creation of new technology.  This protection allows us to operate unhindered in the US market, gives our customers the added confidence to invest in InSphero technology as their platform of choice for 3D cell culture, and provides the grounds necessary to defend against industry competitors attempting to imitate our technology.”

Granting of the patent on September 8 followed InSphero’s recent completion of a Series C financing round, and August announcement naming PerkinElmer as the exclusive global distributor of InSphero hanging drop and ultra-low attachment (ULA) plates for 3D cell culture. 

For more information about InSphero, visit www.insphero.com

 

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jan Lichtenberg
CEO and Co-Founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

InSphero Granted Hanging Drop Patent in United States

05.08.2015 - InSphero Expands Global Availability of its Patented 3D Cell Culture Platforms

InSphero Expands Global Availability of its Patented 3D Cell Culture
Platforms

Schlieren, Switzerland, August 5, 2015 – PerkinElmer named as exclusive distributor of InSphero state-of-the-art 3D culture
technology. 
PDF Version

InSphero AG, the leading supplier of easy-to-use solutions for production, culture, and assessment of more organotypic 3D cell culture models, announced today that its patented GravityPLUS™ Hanging Drop System and new GravityTRAP™ Ultra-Low Attachment (ULA) Plates are now available for purchase exclusively through PerkinElmer.

InSphero will now broaden global access to its 3D cell culture plates, while simplifying ordering and delivery logistics for a worldwide customer base. Working with PerkinElmer, InSphero will be better able to meet increasing demand for reliable methods to grow cells as more biologically relevant 3D spheroids. Furthermore, this agreement will provide additional capabilities to PerkinElmer’s extensive portfolio of consumables, assays, and imaging systems, which the two companies have used to develop novel assays for drug discovery, safety, and efficacy testing.

“The agreement immediately accelerates our ability to efficiently supply and deliver InSphero plate technologies internationally, and also forges a strategic relationship for the continued development of next-generation 3D cell culture platforms, as well as 3D-optimized imaging and cell-based assay protocols,” says Dr. Jan Lichtenberg, CEO and co-founder of InSphero.

Lichtenberg notes that the relationship between the two companies has already yielded novel, high content imaging applications for assessing compound toxicity in liver microtissues, and enabled users to perform RNA interference screens to sensitize tumor spheroids to radiation in research applications.

“Our customers will benefit from PerkinElmer's global reach and technical expertise in experimental workflows when ordering and using InSphero plates. Our reliable, automation-compatible 3D cell culture platforms complement PerkinElmer’s assays and high-content imaging systems,” said Dr. Lichtenberg.

For more information about InSphero, visit www.insphero.com.

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jan Lichtenberg
CEO and Co-Founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

08.07.2015 - InSphero AG Secures CHF 20 Million Series C Financing

InSphero AG Secures CHF 20 Million Series C Financing

Schlieren, Switzerland, July 8, 2015 – Leading 3D cell culture company gains new long-term investor to fuel expansion of global operations and product portfolio.  PDF Version

InSphero AG, the world's leading developer of easy-to-use solutions for organotypic 3D cell culture models and body-on-a-chip systems, has secured CHF 20 million in financing from the family investment office of a globally active entrepreneur represented through HP WILD HOLDING AG based in Zug, Switzerland. InSphero is using the Series C financing round to rapidly expand its global footprint, broaden its portfolio of novel 3D microtissues and contract research services for 3D drug safety and efficacy testing, and develop new products and applications based on its proven technology.

Since its commercial launch in 2010, the company has experienced strong year-over-year sales growth marked by the rapid adoption of its 3D InSight™ microtissues and services by leading pharmaceutical, chemical and cosmetics companies. Since last year, large pharma organizations have begun converting from conventional assays to InSphero's 3D microtissues.

Dr. Jan Lichtenberg, CEO and co-founder of InSphero, says that the investment round enables InSphero to leverage the successful customer implementations, robust validation data, and growing scientific evidence to become the gold standard in the field of 3D cell-based assays.

"This investment is an affirmation of InSphero's valuable, more predictive liver, islet and tumor model systems for use throughout the drug development process," said Lichtenberg. "The family office behind HP WILD HOLDING AG brings to InSphero long-term perspective as well as decades of experience building global brands and driving operational excellence. Their financial commitment is also strengthened by an established international network that will help us better serve growing global demand for microtissues and services, particularly in North America and Asia."

The proceeds of the financing round will be invested to expand InSphero's North American scientific staff and operations into a state-of-the art bio-production facility; increase the variety of model systems available to customers across different industries; and to develop new products including InSphero's Body-on-a-Chip technology and personalized-medicine kits to maturity.

InSphero's pipeline includes 3D liver, skin, heart, brain and tumor models developed for toxicity testing and disease modeling, as well as next-generation 3D cell culture platforms.

For more information about InSphero, visit www.insphero.com.

InSphero contact

Dr. Randy Strube
Director of Global Marketing
Phone +1 800-779-7558 ext. 102
This email address is being protected from spambots. You need JavaScript enabled to view it.

Dr. Jan Lichtenberg
CEO and Co-Founder
Phone +41 44 5150490
This email address is being protected from spambots. You need JavaScript enabled to view it.

About InSphero

InSphero provides superior biological relevance to in vitro testing with its easy-to-use solutions for production, culture and assessment of more organotypic 3D cell culture models. The company's patented 3D cell culture platforms and methods enable large-scale, reproducible production of a broad range of assay-ready 3D InSight™ Microtissues derived from liver, pancreas, tumor, heart, brain and skin. These models and contract research services utilizing them help to identify promising drugs and toxic liabilities with greater predictivity at early development stages, enabling better pre-clinical decision making, saving development cost, and shortening time to market. InSphero's technologies drive significant findings in peer-reviewed journals, through collaborative projects such as EU Body on a Chip and HeCaToS, and validation in the world's largest government institutions and pharmaceutical, chemical and cosmetics companies. This 3D know-how is now also being applied in the diagnostics field to aid development of personalized chemotherapeutic strategies for the treatment of cancer.

Founded in 2009, the privately held company is headquartered in Schlieren, Switzerland with subsidiaries in the United States (Brunswick, ME) and Waldshut, Germany. It has been recognized for its scientific and commercial achievements with a number of national and international awards.

Follow us on Twitter and www.insphero.com.

07.05.2015 - InSphero Launches Enhanced Ultra-low Attachment Spheroid Plate for Scaffold-free 3D Cell Culture

InSphero Launches Enhanced Ultra-low Attachment Plate
for Scaffold-free 3D Cell Culture

Schlieren, Switzerland, May 7, 2015 – GravityTRAP™ ULA Plate design simplifies medium exchange and improves imaging during spheroid production and culture.  PDF Version

InSphero AG, the leading provider of scaffold-free 3D microtissues, cell culture technology, and 3D-focused contract research testing, announced today the release of their new GravityTRAP™ Ultra-low Attachment (ULA) Plate. The automation-compatible 96-well ULA format expands InSphero's portfolio of tissue culture platforms for scaffold-free 3D cell culture, offering a low-cost, enhanced ULA plate ideal for production of 3D tumor microtissues derived from tumor cell lines, or to screen for the propensity of cells to form spheroids in a low-attachment environment.

The GravityTRAP™ ULA Plate includes wells specially coated to prevent attachment and monolayer growth of cells, and provides significant advantages over existing ultra-low attachment spheroid plates, including simplified medium exchange and improved imaging. Each well incorporates a SureExchange™ tapered ledge design that simplifies the process of changing growth medium during long term culture or compound dosing, and protects spheroids from disruption or accidental aspiration. The narrow (1 mm diameter) growth chamber in each well features a flat bottom, eliminating focal distortion that can
complicate imaging in round-bottom ULA plates.  The narrow chamber provides the necessary concentration of cells required to promote formation of a single microtissue per well, while making it easier to locate and image even small (<100 μm diameter) spheroids.

Users of InSphero's GravityPLUS™ hanging drop system will likely be familiar with the GravityTRAP™ ULA Plate, as it already serves as the long-term culture and assay plate provided with the patented hanging drop system. Dr. Simon Messner, Product Manager at InSphero, notes offering the GravityTRAP™ ULA Plate as a stand-alone platform offers a cost-effective option for researchers looking to move their cell culture into 3D, or who may currently be experiencing the limitations of existing ultra-low attachment plates. "We recommend the GravityTRAP™ ULA Plate as a first-line option for testing or confirming the spheroid-forming capacity of cells, particularly tumor cell lines, as they may not require the improved oxygenation and complete elimination of cell-surface interaction afforded by the hanging drop technique to form spheroids. The GravityPLUS™ system is still the platform of choice for production of more  complex 3D microtissues, such as those derived from patient- or animal-derived (primary) cells or multi-cell type co-culture models."

InSphero CEO and co-founder Dr. Jan Lichtenberg states the benefits of the new platform extend beyond its design features. "With the GravityTRAP™ ULA Plate and GravityPLUS™ system, researchers have not only two reliable scaffold-free platforms, but also the confidence of purchasing their technology from a company with extensive 3D cell culture experience and know-how. This includes specially formulated growth medium to promote spheroid formation or long-term culture maintenance, 3D-optimized protocols to help extract the most data, and custom model development and compound screening through our 3D InSight™ Services."

To find out more about the benefits of scaffold-free 3D cell culture, or to learn more about InSphero visit www.insphero.com.

InSphero contact

Dr. Randy Strube, Director of Global Marketing
Phone +1 800-779-7558 ext. 102, This email address is being protected from spambots. You need JavaScript enabled to view it., www.insphero.com

Dr. Jan Lichtenberg, CEO and Co-Founder
Phone +41 44 5150490, This email address is being protected from spambots. You need JavaScript enabled to view it., www.insphero.com

About InSphero

InSphero is the world's leading supplier of organotypic, biologically relevant in vitro 3D microtissues for highly predictive drug testing. The company, headquartered in Zurich, Switzerland, with subsidiaries in the USA and in Germany, currently counts all of the top 15 global pharmaceutical and cosmetics companies as customers. InSphero 3D Insight™ Microtissues enable more biologically relevant in vitro applications in efficacy and toxicology. The spin-off company of the Swiss Federal Institute of Technology (ETH) Zurich and the University Zurich has been recognized for its scientific and commercial achievements with a number of national and international awards, including being named the #1 Swiss Startup and ACES Award Winner for 2014. InSphero is certified to the ISO 9001:2008 standard for its Quality Management System.

Follow us on twitternewsletter and www.insphero.com

17.03.2015 - InSphero Publication Honored for Potential to Reduce Use of Research Animals

InSphero Publication Honored for Potential to Reduce Use of Research Animals

Schlieren, Switzerland, March 17, 2015 – Nature Communications paper co-authored with ETH Zurich wins "highly commended" honor from NC3Rs.  PDF Version

Research conducted by InSphero AG, the world’s leading supplier of 3D microtissues for in vitro safety and efficacy testing, and collaborators at ETH Zurich has received the “highly commended” honor from the British National Center for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs). Dr. Olivier Frey of ETH Zurich, first author on the paper published last June in the journal Nature Communications, accepted the award at the 3Rs Prize ceremony held last week in London.

The paper, entitled “Reconfigurable microfluidic hanging drop network for multi-tissue interaction and analysis,” reported a novel approach to culturing multi-cellular 3D microtissues in vitro, and for the first time joined hanging drop cell culture with microfluidics. Growing spheroids in hanging drops removes restrictions associated with scaffolds, while microfluidics allow continuous medium and waste exchange, and allowing test substances such as candidate drugs to be dosed into the culture medium. The body-on-a-chip (BoC) system successfully displayed the ability to interconnect spheroids from two different tissue types (liver and tumor) which were able to communicate with each other via metabolite transfer. The principle was demonstrated using bioactivation of the anti-cancer drug Cyclophosphamide by the liver, and subsequent inhibition of tumor spheroid growth.

Dr. Jan Lichtenberg, CEO and co-founder of InSphero commented,”Multi-tissue in vitro test systems hold promise in the drug development industry as a better means of predicting the safety and efficacy of novel agents, while reducing the dependency on using animals for such studies.” Lichtenberg noted most BoC concepts to date focus on joining individual chambers of cells cultured in 2-dimensional monolayers, which is the current industry standard for most in vitro cell based assays. “Our 3D InSight™ Liver, Islet, and Tumor Microtissues continue to provide striking evidence that 3D cell culture displays a more organotypic, biologically relevant phenotype than 2D. Naturally it follows that interconnecting spheroids would be an ideal approach to recapitulating a multi-organ system, something this research conceives in a scalable and flexible BoC format.”

The collaboration has yielded two additional publications since the award winning Nature Communications paper last June, including recent articles in the Journal of Laboratory Automation and the Journal of Biotechnology.

NC3Rs is a UK-based scientific organization dedicated to replacing, refining and reducing the use of animals in research and testing. The 3Rs Prize is sponsored by GlaxoSmithKline.

For more information about InSphero, visit www.insphero.com.

InSphero contact

Dr. Randy Strube, Director of Global Marketing
Phone +1 800-779-7558 ext. 102, This email address is being protected from spambots. You need JavaScript enabled to view it., www.insphero.com

Dr. Jan Lichtenberg, CEO and Co-Founder
Phone +41 44 5150490, This email address is being protected from spambots. You need JavaScript enabled to view it., www.insphero.com

About InSphero

InSphero is a leading supplier of organotypic, biological in vitro 3D microtissues for highly predictive drug testing. The company, headquartered in Zurich, Switzerland, with subsidiaries in the USA and in Germany, currently counts all of the top ten global pharmaceutical and cosmetics companies as customers. InSphero 3D Insight™ Microtissues enable more biologically relevant in vitro applications in efficacy and toxicology. The spin-off company of the Swiss Federal Institute of Technology (ETH) Zurich and the University Zurich has been recognized for its scientific and commercial achievements with a number of national and international awards, including being named the #1 Swiss Startup for 2014. InSphero is certified to the ISO 9001:2008 standard for its Quality Management System.

Follow us on twitternewsletter and www.insphero.com

10.03.2015 - Proteomic Profiling of 3D Liver Microtissues Provides New Insight Into Acetaminophen Toxicity

Proteomic Profiling of 3D Liver Microtissues Provides New Insight Into Acetaminophen Toxicity

Schlieren-Zurich, Switzerland, March 10, 2015 – InSphero, Biognosys paper reveals relevant proteomic changes in liver at sub-toxic doses.  PDF Version

InSphero AG, a leading supplier of 3D microtissues for in vitro safety and efficacy testing, and Biognosys AG, a leader in next-generation proteomics have teamed up to publish research in Molecular & Cellular Proteomics entitled "Extending the limits of quantitative proteome profiling with data-independent acquisition and application to acetaminophen treated 3D liver microtissues". The paper represents the latest milestone in characterizing InSphero's 3D microtissues as a superior model system for in vitro toxicity testing. The study was co-authored by researchers from Purdue University and ETH Zurich, and will be presented at the upcoming Society of Toxicology meeting in San Diego, California.

In the study, proteomic changes in acetaminophen (APAP)-treated 3D InSight™ Human Liver Microtissues were quantified with HRM-MS™, a next-generation proteomics technology developed by Biognosys that is based on data-independent acquisition (DIA) performed on new generation mass spectrometric systems. The abundance of 2,830 proteins was quantified over an APAP physiological concentration range with a starting material of 12,000 cells per sample. Proteins from all three phases of drug metabolism were identified as regulated. Moreover, for the first time the exact NAPQI‐cysteine adduct sites were mapped on proteins possibly relevant for the toxicity of APAP.

Dr. Jens M. Kelm, CSO and co-founder of InSphero stated "the combination of our organotypic 3D microtissue model system and the HRM profiling technology proved to be a powerful approach for discovery experiments, revealing novel modes‐of‐action, toxicity upon drug treatment, and new biomarkers. HRM-MS makes yet another useful endpoint available to our customers for extracting high-value information from our microtissues, particularly global proteomic changes in response to drug treatment."

Dr. Kelm noted the enhanced longevity and more native metabolic phenotype of 3D microtissues made them suitable for such long-term, repeat-dose toxicity studies, and importantly, the HRM approach was able to identify and quantify for the first time human protein targets of drug-adducts in sub-toxic APAP concentrations. InSphero's 3D InSight™ Human Liver Microtissues are established using primary human hepatocytes (PHH) and other non-hepatocyte liver cells using a proprietary process and the company's hanging drop platform.

For more information about InSphero, visit www.insphero.com.

InSphero contact

Dr. Randy Strube, Director of Global Marketing
Phone +1 800-779-7558 ext. 102, This email address is being protected from spambots. You need JavaScript enabled to view it., www.insphero.com

Dr. Jens M Kelm, CSO and Co-Founder
Phone +41 44 5150490, This email address is being protected from spambots. You need JavaScript enabled to view it., www.insphero.com

About InSphero

InSphero is a leading supplier of organotypic, biological in vitro 3D microtissues for highly predictive drug testing. The company, headquartered in Zurich, Switzerland, with subsidiaries in the USA and in Germany, currently counts all of the top ten global pharmaceutical and cosmetics companies as customers. InSphero 3D Insight™ Microtissues enable more biologically relevant in vitro applications in efficacy and toxicology. The spin-off company of the Swiss Federal Institute of Technology (ETH) Zurich and the University Zurich has been recognized for its scientific and commercial achievements with a number of national and international awards, including being named the #1 Swiss Startup for 2014. InSphero is certified to the ISO 9001:2008 standard for its Quality Management System.

Follow us on twitternewsletter and www.insphero.com

About Biognosys

Biognosys is the leading proteomics company offering services and products for highly multiplexed protein quantification. Founded in 2008 as a spin-off
from the lab of proteomics pioneer Ruedi Aebersold at ETH Zurich, Biognosys is dedicated to transform life science with superior technology and software.

Contact: This email address is being protected from spambots. You need JavaScript enabled to view it., www.biognosys.ch

21.01.2015 - 3D Liver Spheroid Model in Use by MIP-DILI, IMI's Drug Liver Injury Project

3D Liver Spheroid Model in Use by MIP-DILI, IMI's Drug Liver Injury Project

Schlieren, Switzerland, January 21, 2015 – European consortium will use 3D liver tissues to better predict drug-induced liver injury.  PDF Version

Leaders of the European project "Mechanism based Integrated systems for the Prediction of Drug Induced Liver Injury" (MIP-DILI) project have reported they will use 3-dimensional (3D) liver spheroids against a panel of other in vitro test systems aimed at developing novel preclinical tests to improve the safety evaluation of drugs likely to cause drug-induced liver toxicity before subsequent evaluation in clinical trials.  Along with its academic and EFPIA partners, the MIP-DILI consortium is funded equally by the EU Innovative Medicines Initiative (IMI) and EFPIA companies, and is in year three of the €32.4 million 5-year program.

In early project work, primary human hepatocytes (PHH), cells isolated from human liver donors, outperformed tumor-derived or other immortalized liver cell lines in terms of metabolic activity but with apparently mixed sensitivity to known DILI-inducing drugs.  InSphero, the leading supplier of 3D cell culture products and services to the  pharmaceutical industry, along with a number of other commercial technology suppliers were invited to participate in the next round of studies, where PHH were grown and assayed in a variety of formats that included static 2D culture, perfusion cultures, and 3D spheroids. Among the participating commercial suppliers contributing to the study, 3D spheroids emerged as the culture platform that most resembled liver-like biology and responded to a number of liver toxins with a certain enhanced sensitivity, which now requires further investigation.

Dr. Phil Hewitt, co-leader of the project's 'Established and novel in vitro cell systems' work package, says "3D spheroids proved to offer more than just superior biological relevance, they also provide the scalability and compatibility necessary to work with commercial assays and automation systems, and can do it at a more reasonable cost than other systems evaluated in the early phase studies.  Liver spheroids will play a key role in the predictive in vitro tests being developed as the project progresses."

The findings were presented last fall at EUROTOX 2014 in Edinburgh, UK, in talks that summarized a thorough two-year evaluation of available liver cell sources and cell culture formats being considered.

InSphero supplies assay-ready 3D microtissues and 3D-focused screening services to the pharmaceutical and cosmetics industry, counting the world's top 15 pharmaceutical companies as their clients.  InSphero's 3D InSight™ Human Liver Microtissues are established using PHH and other non-hepatocyte liver cells using a proprietary process and the company's hanging drop platform.  Growing the cells in 3D results in a long-lived microtissue that more accurately mimics the cell architecture and metabolic phenotype of native liver compared to traditional 2D cultured PHH.

For more information about InSphero, visit www.insphero.com.

InSphero contact

Dr. Randy Strube, Director of Global Marketing, phone +1 800-779-7558 ext. 102, This email address is being protected from spambots. You need JavaScript enabled to view it., www.insphero.com

Dr. Jan Lichtenberg, CEO and Co-Founder, phone +41 44 5150490, This email address is being protected from spambots. You need JavaScript enabled to view it.www.insphero.com

Disclaimer

MIP-DILI is jointly funded by EFPIA and Innovative Medicines Initiative. The press release by no means endorses MIP-DILI or its members in using InSphero products for drug discovery & development. MIP DILI endorses/recognizes the imperative value of comparing the quantitative evaluation of all test systems for drug safety evaluation in line with its primary objective http://www.mip-dili.eu/

About InSphero

InSphero is a leading supplier of organotypic, biological in vitro 3D microtissues for highly predictive drug testing. The company, headquartered in Zurich, Switzerland, with subsidiaries in the USA and in Germany, currently counts all of the top ten global pharmaceutical and cosmetics companies as customers. InSphero 3D Insight™ Microtissues enable more biologically relevant in vitro applications in efficacy and toxicology. The spin-off company of the Swiss Federal Institute of Technology (ETH) Zurich and the University Zurich has been recognized for its scientific and commercial achievements with a number of national and international awards, including being named the #1 Swiss Startup for 2014. InSphero is certified to the ISO 9001:2008 standard for its Quality Management System.

Follow us on twitternewsletter and www.insphero.com

 

Media Release images

For a high-resolution view click on an image below.

28.05.2014
Pancreatic Microislets for Diabetes

Media release 28.05.2014 - Pancreatic Microislets for Diabetes

11.04.2014
Dainippon Screen Cell3iMager

Media release 11.04.2014 - Dainippon Screen Cell3iMager

11.04.2014
96well Spheroids

Media release 11.04.2014 - 96well Spheroids

11.04.2014
Tumor Spheroid

Media release 20.03.2014 - Tumor Spheroid

 

20.03.2014
3D Tumor Microtissue

Tumor cells grown in 3D spheroids

27.02.2014
GravityPLUS plate

gravity-plus-culture-assay-96-plate

27.02.2014
3D InSight Tumor Microtissue

insphero-tumor-microtissue2

30.01.2014
Rat Liver

inspherp-rat-liver-thumb

28.01.2014
R. Strube

insphero-randy-strube-thumb

 

Media Releases Archive

Company video

company-video-inspheor